carzelesin and Colonic-Neoplasms

carzelesin has been researched along with Colonic-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for carzelesin and Colonic-Neoplasms

ArticleYear
Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors.
    Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:1

    The therapeutic efficacy of the sequence-selective, DNA minor-groove-binding alkylating agent carzelesin was evaluated against a series of human tumor xenografts growing at the s.c. site. The model consisted of seven colon adenocarcinomas, and six pediatric rhabdomyosarcomas. In addition, carzelesin was evaluated against xenografts selected in situ for resistance to vincristine, melphalan, and topotecan. Carzelesin was given as a single i.v. injection, and tumor volumes were determined at 7-day intervals. At the highest dose [0.5 mg/kg, the dose producing 10% lethality (LD10)]), carzelesin significantly inhibited growth in four of six colon tumor lines, causing a high proportion of partial regressions in one of seven lines and complete regressions of VRC5 colon tumors. At 0.25 mg/kg, significant growth inhibition was determined in only two of seven colon tumor lines with infrequent volume regressions. Carzelesin given at the highest nonlethal dose level significantly inhibited the growth of each of six rhabdomyosarcomas, causing a high frequency of partial or complete regressions in four of six tumor lines. There was no apparent cross-resistance to carzelesin in two rhabdomyosarcomas selected for vincristine resistance (Rh12/VCR, Rh18/VCR) or in Rh28/LPAM xenografts selected for primary resistance to the bifunctional alkylating agent melphalan. Interestingly, carzelesin maintained full activity against Rh18/TOPO tumors selected in situ for resistance to topotecan, whereas the colon tumor VRC5/TOPO, selected in a similar manner, was completely resistant to this agent.

    Topics: Adenocarcinoma; Adolescent; Adult; Animals; Antineoplastic Agents; Benzofurans; Child; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Duocarmycins; Female; Humans; Indoles; Lethal Dose 50; Male; Mice; Mice, Inbred CBA; Rhabdomyosarcoma; Transplantation, Heterologous; Tumor Cells, Cultured

1995
Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue.
    Cancer research, 1992, Sep-15, Volume: 52, Issue:18

    The cyclopropylpyrroloindole analogues are DNA minor-groove binders containing a cyclopropyl group, which mediates N3-adenine covalent adduct formation in a sequence-selective fashion. Carzelesin (U-80244) is a cyclopropylpyrroloindole prodrug containing a relatively nonreactive chloromethyl precursor to the cyclopropyl function. Activation of carzelesin requires two steps, (a) hydrolysis of a phenylurethane substituent to form U-76073, followed by (b) ring closure to form the cyclopropyl-containing DNA-reactive U-76074. The formation of the DNA-reactive U-76074, via U-76073, from carzelesin was shown to proceed very slowly in phosphate-buffered saline (t1/2 greater than 24 h) but to occur rapidly in plasma from mouse, rat, dog, and human (initial t1/2 values ranging from 18 min for mouse to 52 min for rat) and in cell culture medium (t1/2 approximately 40 min). Although carzelesin was less potent in terms of in vitro cytotoxicity and in vivo optimal dosage and showed low affinity for binding to DNA, it was therapeutically more efficacious against mouse L1210 leukemia than was U-76074 or adozelesin (U-73975), another cyclopropylpyrroloindole analogue which is currently in phase I clinical trials. Carzelesin also proved to be more efficacious than U-76074 or adozelesin against mouse pancreatic ductal 02 adenocarcinoma, a system reported to be resistant to every agent tested. Carzelesin was highly effective against this tumor and produced 97% tumor growth inhibition. In addition, i.v. administered carzelesin showed significant activity (National Cancer Institute criteria) against i.v. or s.c. implanted Lewis lung carcinoma, i.p. or s.c. implanted B16 melanoma, s.c. implanted colon 38 carcinoma, and five s.c. implanted human tumor xenografts, including clear cell Caki-1 carcinoma, colon CX-1 adenocarcinoma, lung LX-1 tumor, ovarian 2780 carcinoma, and prostatic DU-145 carcinoma. Carzelesin treatment produced 100% complete remissions (no palpable tumor mass at the termination of the experiment) in mice bearing early-stage human ovarian 2780. Pharmacologically, carzelesin proved to be relatively schedule and route independent and was highly active against i.p. implanted L1210 leukemia, regardless of whether the analogue was given i.v., i.p., s.c., or p.o. These results, collectively, suggest that carzelesin is absorbed and distributed well. Both carzelesin and adozelesin caused marked tumor shrinkage in mice bearing human lung LX-1 or advanced-stage human ovar

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzofurans; Cell Survival; Colonic Neoplasms; Culture Media; Duocarmycins; Indoles; Leukemia L1210; Metabolic Clearance Rate; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Plasma; Prodrugs; Transplantation, Heterologous

1992